Recon: China Says New Coronavirus Can Spread From Human to Human; GSK, 23andMe Seek First Drug Target

• Despite US law, many clinical trial results go unreported (Reuters) (The Lancet)
• FDA delays decision on Intercept's NASH drug by three months (PMLive) (BioPharmaDive)
• Patients Still Struggle To Balance High Costs Of MS Treatment, Despite Generic (NPR)
• Judge slashes $8B Risperdal award against J&J to $6.8M (Reuters) (NYTimes)
• Medicare’s Part D Doughnut Hole Has Closed! Mostly. Sorta. (NYTimes)
• Supreme Court to hear Trump appeal in Obamacare contraception fight (Reuters)
• US to screen passengers for new China coronavirus at three airports (Reuters)

• China Confirms New Coronavirus Spreads From Humans to Humans (NYTimes)
• Virus spreads to more Chinese cities, President Xi says containment is priority (Reuters)
• China’s plan to slash health care costs sees global pharmaceutical firms crowded out of market (SCMP)
• WHO Warns That Pipeline for New Antibiotics Is Running Dry (NYTimes)
• EPO officially cancel the Broad Institute's CRISPR patent (BioNews) (GenomeWeb)
• GSK and gene profiling group 23andMe seek first drug target (Financial Times)
• Heart failure market could surpass ‘$22bn by 2028’ (PharmaTimes)
• UK records 178 medicine shortages in 2019, say reports (EPR)
• What ails India's pharmaceutical sector? (Economic Times)

• Deciphering a cancer treatment’s dark side (Science)
• Could a drug for arthritis in dogs also fight cancer in people? (Boston Globe)
• After big year, RNAi drugmakers compete to prove what comes next (BioPharmaDive)
• JPM: Glaxo's cancer unit, in commercial 'building mode,' gets choosy with M&A (Fierce)
• JPM: Biotech, VC execs on where the industry should look beyond cancer (Fierce)
• Your heartburn drug has been recalled. Now what? (NBC)
• Moffitt Cancer Center details links of fired scientists to Chinese talent programs (Science)
• US-China trade deal fails to address opioids (AEI)
• Merck looks to CMOs to help ease vaccine supply bottleneck (Outsourcing Pharma)
• FDA Panels Show Little Love for New Painkillers (Medpage)
• Unapproved Drug for Babies? Ethics Experts Weigh In (Medpage)
• Biosimilars for Rheum Disease: Failure to Launch (Medpage)
• FDA Harnesses Technology and Collaboration to Support Rare Disease Product Development (FDA)
• Strides arm receives EIR for its US facility (Economic Times)
• Revolution Med shoots for $100M+ IPO — and divulges some secrets about that Warp Drive buyout (Endpoints)
• At #JPM20, two CEOs, two radically different therapies, and a fight to chase down sickle cell (Endpoints)
• Edible security tag for drugs developed to combat counterfeits (EPR)
• FUSION IV Pharmaceuticals, Inc dba. AXIA Pharmaceutical Issues Voluntary Nationwide Recall of All Sterile Drug Products Within Expiry Due to A Lack of Assurance of Sterility (FDA)

• J&J pushes to expand Imbruvica label after clinical success (PMLive) (Press)
• AstraZeneca Announces Positive FDA Updates on Cancer Drugs (Press)
• AZ’s Imfinzi scores orphan drug status in liver cancer (PMLive)
• Bridge Biotherapeutics Announces FDA IND Clearance for BBT-176, an EGFR TKI for NSCLC (Press)
• Medivir's Phase II Study of MIV-711 in Patients With Osteoarthritis Published in Annals of Internal Medicine (Press)

• FDA to EPA: Leave us out of your ethylene oxide rule (Medical Design & Outsourcing)

• Boston Scientific to appeal order to finish failed $275M merger (MassDevice)
• Breaking News – Supreme Court Personal Jurisdiction Certiorari Grants (Drug & Device Law)
• Plaintiffs Win – The Public Loses (Drug & Device Law)
• BioDelivery Sciences International, Inc. v. Aquestive Therapeutics, Inc. (Fed. Cir. 2020) (Patent Docs)
• High Court ERISA Case Has States, Pharmacies On Edge (Law360-$)

• FDA Advisory Committee Calendar
• The Oncology Center of Excellence (OCE), Envisioning Oncology Product Development for 2025 – 5 February 2020
• Vaccines and Related Biological Products Advisory Committee March 4, 2020 Meeting Announcement – 4 March 2020

• Information for all Swiss manufacturers of medical devices Third country compliance for all products (MDR and MDD) from 26 May 2020 is currently the realistic «worst case scenario» (Swiss Medtech)

• Zydus & CMS enter pact for Desidustat in Greater China (Economic Times)
• Report of the PMDA-ATC GMP Inspection Seminar 2019 (PMDA)

• Pain for big Indian pharma companies continue warns CRISIL, as FDA woes remains unresolved (Economic Times)
• Biocon Bengaluru unit pre-approval inspection by USFDA concludes with zero observations (Economic Times)
• Lupin gets 5 observations from USFDA for its Vizag facility (Economic Times)
• Cipla announces closure of USFDA inspection at Patalganga facility (Economic Times)
• DoP rejects Sun Pharma’s review petition on ciprofloxacin hydrochloride injection (PharmaBiz)

• Consultation: Fees and charges proposal 2020-21 (TGA)
• New science strategy prepares regulatory scientists for the future (TGA)

• Paraguay braces for deadly Dengue fever outbreak (Reuters)

• Epic Systems, a major medical records vendor, is warning customers it will stop working with Google Cloud (CNBC)